Category - Markets

Closely-held BioSight has closed an investment of $13-million led by Mori Arkin’s pharmaceutical investment firm, Arkin Holdings, and the U.S.-based venture firm, Primera Capital. Proceeds will be used for a multi...

Leerink Partners has launched coverage of American Renal Associates (NYSE:ARA) with an “outperform” rating and $33 price target. The stock closed at $27.71 on Friday. “Our positive thesis contemplates a forward adjusted...

Leerink has initiated coverage of Theravance Biopharma (NASDAQ:TBPH) with an “outperform” rating and $26 price target. The stock closed at $18.10 on Wednesday. Theravance was formed in 2014 via a spin out from Innovia...

Rodman & Renshaw has initiated coverage of Presbia PLC (NASDAQ:LENS) with the “buy” rating and 18-month price target of $14. The stock closed at $3.90 on Tuesday. Presbia has a novel corneal inlay product, the...

Roth Capital Partners has reinitiated coverage on NeoGenomics with a “buy” rating and target price of $10, following its acquisition of Clarient from GE Healthcare. The stock closed at $8.34 on Tuesday. “We believe...

Rodman & Renshaw has initiated coverage of LabStyle Innovations (NASDAQ:DRIO) with a “buy” rating and $12 price target. The stock closed at $5.40 on Friday. LabStyle is an emerging digital health company focused on...

Maxim Group has initiated coverage of ContraVir Pharmaceuticals (NASDAQ:CTRV) with a “buy” rating and price target of $4, calling the company an emerging anti-viral leader with two clean shots on goal. The stock closed...

TearLab (NASDAQ:TEAR; TSX:TLB) has priced a public offering of common stock to raised gross proceeds of approximately $17.3-million to close on May 9. The offering was priced at 75 cents a share of common stock, or...

First quarter revenue for TearLab (NASDAQ:TEAR; TSX:TLB) rose 25% to $6.8-million from $5.4-million a year ago. A net total of 257 TearLab Osmolarity Systems were added in the first quarter of 2016, of which 167 were...

Leerink has downgraded Sarepta Therapeutics (NASDAQ:SRPT) to “under perform” and slashed its price target to $5 from $13. The stock closed at $17.92 on Monday. Sarpeta has been a confounding stock for which to forecast...